Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rallied 2.73% to $9.02 Wednesday, on what proved to be an all-around ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.22% to $8.78 Tuesday, on what proved to be an all-around mixed ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced that data from its US and UK first-in-human dose escalation ...

HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...

Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corbus Pharmaceuticals (CRBP – Research ...

Corbus Pharmaceuticals Holdings, Inc. has announced the release of an abstract for its first-in-human dose escalation clinical study of CRB-701 (SYS6002), which targets Nectin-4 in patients with ...

Corbus Pharmaceuticals Holdings ... clinical study of CRB-701 (SYS6002), a novel cancer treatment. The company's stock has experienced significant volatility, having declined over 80% in the ...